These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19691116)

  • 1. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
    Ravina B; Tanner C; Dieuliis D; Eberly S; Flagg E; Galpern WR; Fahn S; Goetz CG; Grate S; Kurlan R; Lang AE; Marek K; Kieburtz K; Oakes D; Elliott R; Shoulson I;
    Mov Disord; 2009 Oct; 24(14):2081-90. PubMed ID: 19691116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Creation and standardized longitudinal follow-up of a cohort of patients with de novo Parkinson's disease: the VIP project].
    Consorcio Parkinson
    Rev Neurol; 2006 Sep 16-30; 43(6):366-73. PubMed ID: 16981168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of weight loss in Parkinson's disease.
    Uc EY; Struck LK; Rodnitzky RL; Zimmerman B; Dobson J; Evans WJ
    Mov Disord; 2006 Jul; 21(7):930-6. PubMed ID: 16534756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
    Martin WR; Wieler M; Gee M
    Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study.
    Liepelt-Scarfone I; Gauss K; Maetzler W; Müller K; Bormann C; Fruhmann Berger M; Timmers M; Streffer J; Berg D
    Neuroepidemiology; 2013; 41(3-4):174-82. PubMed ID: 24051361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we image premotor Parkinson disease?
    Marek K; Jennings D
    Neurology; 2009 Feb; 72(7 Suppl):S21-6. PubMed ID: 19221310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The search for biomarkers in Parkinson's disease: a critical review.
    Antoniades CA; Barker RA
    Expert Rev Neurother; 2008 Dec; 8(12):1841-52. PubMed ID: 19086880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
    Doan JB; Melvin KG; Whishaw IQ; Suchowersky O
    Behav Brain Res; 2008 Dec; 194(2):207-13. PubMed ID: 18692094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.
    Berger K; Breteler MM; Helmer C; Inzitari D; Fratiglioni L; Trenkwalder C; Hofman A; Launer LJ
    Neurology; 2000; 54(11 Suppl 5):S24-7. PubMed ID: 10854358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort.
    Uitti RJ; Baba Y; Wszolek ZK; Putzke DJ
    Parkinsonism Relat Disord; 2005 May; 11(3):139-45. PubMed ID: 15823477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ATTEMPT cohort: a multi-national longitudinal study of predictors, patterns and consequences of smoking cessation; introduction and evaluation of internet recruitment and data collection methods.
    West R; Gilsenan A; Coste F; Zhou X; Brouard R; Nonnemaker J; Curry SJ; Sullivan SD
    Addiction; 2006 Sep; 101(9):1352-61. PubMed ID: 16911736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.
    Foulds PG; Mitchell JD; Parker A; Turner R; Green G; Diggle P; Hasegawa M; Taylor M; Mann D; Allsop D
    FASEB J; 2011 Dec; 25(12):4127-37. PubMed ID: 21865317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease.
    Michell AW; Luheshi LM; Barker RA
    Neurosci Lett; 2005 Jun; 381(3):294-8. PubMed ID: 15896487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of dysprosody in Parkinson's disease over time--a longitudinal study.
    Skodda S; Rinsche H; Schlegel U
    Mov Disord; 2009 Apr; 24(5):716-22. PubMed ID: 19117364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.